Use of vasoactive drugs in the treatment of shock.
The effective use of vasoactive drugs in shock requires an understanding of the pathophysiologic mechanisms involved in the various types and stages of shock and knowledge of the specific pharmacologic effects of each drug in the abnormal state. Vasoactive drugs should be used after the primary and secondary causes of shock have been corrected. Specific vasoactive drugs should be selected on the basis of measured hemodynamic abnormalities.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000627:therapeutic use; D002302:Cardiac Output / Q000187:drug effects; D002395:Catecholamines / Q000378:metabolism; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008729:Methoxamine / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D002395:Catecholamines; D004071:Digitalis Glycosides; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D005934:Glucagon; D011433:Propranolol; D008729:Methoxamine; D007545:Isoproterenol; D002118:Calcium; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine